BioSpace News Archive

Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, is presenting preclinical data today on KPMW135, a novel CD3 x CD20 bispecific molecule developed with Kleo’s multi-targeted antibody therapy enhancer (MATE™) conjugation platform.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of key preclinical data from its lead program, NX-2127, for the potential treatment of B-cell malignancies, at the 62 nd American Society of Hematology (ASH) Annual Meeting and Exposition. Supported by these data, Nurix plans to initiate a Phase 1 clinical trial of orally administered NX-2127 in

ALLO-605 Demonstrated Enhanced Killing of Multiple Myeloma Cells and Persistence Relative to BCMA CAR T TurboCAR Technology Represents a Key Component to the Company’s Three-Pronged Clinical Strategy Targeting BCMA for Multiple Myeloma Investigational New Drug (IND) Application for ALLO-605 Expected in the First Half of 2021

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two triple therapy combination data

62% overall response rate in BTK pre-treated CLL/SLL patients, rising to 84% in patients followed for 10 or more months; consistent response rates regardless of reason for prior BTK discontinuation or BTK mutation status Similar overall response rates observed in patients previously treated with all classes of available therapy (chemotherapy, anti-CD20 antibodies, BTK inhibitors, BCL2 inhibitors, PI3K-delta inhibitors) 94% of responding patients remain in response and on ther

Economic activity in the hospital subsector grew in November for the sixth consecutive month, say the nation’s hospital supply executives in the latest Hospital ISM® Report On Business®.

Phase 2 GRIFFIN data presented at ASH 2020 show increased stringent complete response and minimal residual disease negativity rates with maintenance therapy for transplant-eligible patients

Further analyses from the Phase 3 ANDROMEDA study at ASH 2020 highlight potential of DARZALEX FASPRO® in treatment of rare blood disease

- STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached - - 1 CR & 2 PRs observed in heavily pretreated patients with DLBCL; 1 SD in marginal zone lymphoma; 2 SDs in follicular lymphoma - Fred Hutchinson preclinical models with STRO-001 identifies CD74 as a potential target for the treatment of AML

Treatment options did not provide hematocrit control consistent with NCCN guidelines for up to 78 percent of patients as presented at the American Society for Hematology (ASH) 2020 annual meeting